Truemeds Acquires DealShare at Steep Discount

In a significant move signaling consolidation within India's digital commerce sector, healthcare platform Truemeds is reportedly in advanced discussions to acquire DealShare, a social commerce pioneer. The transaction, valued at approximately $90 million, would be structured as a share-swap, marking a dramatic shift for DealShare, which achieved unicorn status just over two years ago.

This proposed acquisition price represents a stark valuation recalibration for DealShare, plummeting roughly 95% from its peak valuation of $1.7 billion reached in early 2022. The sharp decline underscores the considerable challenges faced by the company in navigating the competitive Indian e-commerce environment. DealShare, founded with the mission to deliver affordable groceries and consumer goods through innovative flash sales and group buying models, had garnered substantial investor confidence.

The company's ascent to unicorn status was cemented in January 2022 with a $105 million Series D funding round led by the Abu Dhabi Investment Authority (ADIA). Prior to this, DealShare had secured significant backing from prominent venture capital firms including Tiger Global, Alpha Wave, and Kora Investment, accumulating approximately $193 million in total funding. However, persistent issues with unit economics, escalating customer acquisition costs, and difficulties in customer retention began to erode its market position.

Adding to its operational woes, DealShare has seen its entire founding team depart. Vineet Rao and Sankar Bora exited in 2023, followed by CEO Sourjyendu Medda in January 2024, and Rajat Shikhar in December 2025. This exodus of leadership has left the company without its original strategic vision and operational continuity, further complicating its path forward.

Under the terms of the potential deal, Truemeds would issue shares valued at an implied $100 million to DealShare's existing investors. Notably, the acquisition price of $90 million is only slightly above DealShare's reported cash reserves exceeding $70 million. This suggests that a key component of the transaction's value lies in the target's available capital rather than its ongoing operational assets or customer base.

This potential merger aligns with broader industry trends of consolidation in India's fragmented e-commerce and social commerce segments. For Truemeds, the acquisition offers a strategic infusion of capital and access to a potentially complementary customer base, opening avenues for cross-selling its healthcare products. For DealShare's investors, including ADIA, Tiger Global, Alpha Wave, and Kora Investment, this represents an opportunity to exit a challenging investment, albeit at a valuation significantly below earlier expectations.